Message Board

Respected readers, authors and reviewers, you can add comments to this page on any questions about the contribution, review,        editing and publication of this journal. We will give you an answer as soon as possible. Thank you for your support!

Name
E-mail
Phone
Title
Content
Verification Code

YANG Xian, ZHENG Ping. Clinical pharmacists participating in antithrombotic treatment in subacute myocardial infarction patient with cerebral lacuna infarction and deep vein thrombosis[J]. Journal of Pharmaceutical Practice and Service, 2017, 35(2): 161-164. doi: 10.3969/j.issn.1006-0111.2017.02.016
Citation: YANG Xian, ZHENG Ping. Clinical pharmacists participating in antithrombotic treatment in subacute myocardial infarction patient with cerebral lacuna infarction and deep vein thrombosis[J]. Journal of Pharmaceutical Practice and Service, 2017, 35(2): 161-164. doi: 10.3969/j.issn.1006-0111.2017.02.016

Clinical pharmacists participating in antithrombotic treatment in subacute myocardial infarction patient with cerebral lacuna infarction and deep vein thrombosis

doi: 10.3969/j.issn.1006-0111.2017.02.016
  • Received Date: 2016-03-24
  • Rev Recd Date: 2016-11-30
  • Objective To discuss antithrombotic drug treatment in subacute myocardial infarction patient with cerebral lacuna infarction and deep vein thrombosis. Methods Clinical pharmacists analyzed the causes of the blood clot formation, assessed ischemia and hemorrhage risk, consulted evidence-based medicine information, put forward reasonable suggestions and monitored the medication efficacy and safety. Results There were a lot of risk factors of thrombosis in this patient who was also at high risk of bleeding. Clinical pharmacists recommended to reduce aspirin dose to 75 mg daily and add proton pump inhibitors. Anticoagulant therapy should also include low molecular heparin. Some suggestions were accepted by doctors. The patient's condition was improved and there was no bleeding during hospitalization. Conclusion Clinical pharmacists assisted doctors in the antithrombotic treatment and maximized medication safety.
  • [1] Ness J,Aronow WS. Prevalence of coronary artery disease,ischemic stroke,peripheral arterial disease,and coronary revascularization in older African-Americans,Asians,Hispanics,whites,men,and women[J].Am J Cardiol,1999,84(8):932-933.
    [2] 朱敏林,梁丽珠,谢玉梅. 急性心肌梗死患者预防并发下肢深静脉血栓的护理方法[J].血栓与止血学,2015,21(3):187-189.
    [3] 中华医学会心血管病学分会,中华心血管病杂志编辑委员会. 中国心血管病预防指南[J]. 中华心血管病杂志,2011,39(1):3-22.
    [4] Alan JG,Martin JA,Joshua IB,et al. Consensus statement by the american association of clinical endocrinologists and american college of endocrinology on the comprehensive type 2 diabetes management algorithm[J].Endocr Pract,2016,22(1):84-113.
    [5] Washam JB,Herzog CA,Beitelshees AL,et al. Pharmacotherapy in chronic kidney disease patients presenting with acute coronary syndrome:A scientific statement from the American Heart Association[J].Circulation,2015,131(12):1123-49.
    [6] 廖敏辉,李平,刘永刚. GRACE与CRUSADE危险评分的相关性研究[J].中国药师,2015,18(3):441-443.
    [7] 中华医学会心血管病学分会,中华心血管病杂志编辑委员会. 非ST段抬高急性冠状动脉综合征诊断和治疗指南[J]. 中华心血管病杂志,2012,40(5):353-367.
    [8] 中华医学会心血管病学分会,中华心血管病杂志编辑委员会. 抗血小板治疗中国专家共识[J]. 中华心血管病杂志,2013,41(3):183-194.
    [9] 抗栓治疗消化道损伤防治专家组. 抗栓治疗消化道损伤防治中国专家建议(2016)[J]. 中华内科杂志,2016,55(7):564-567.
    [10] 中华医学会外科学分会,血管外科学组. 深静脉血栓形成的诊断和治疗指南[J]. 中华普通外科杂志,2012,50(7):611-614.
    [11] 中华医学会神经病学分会,中华医学会神经病学分会脑血管病学组. 中国急性缺血性脑卒中诊治指南(2014)[J]. 中华神经科杂志,2015,48(4):246-257.
    [12] 中华医学会神经病学分会,中华医学会神经病学分会脑血管病学组. 中国缺血性脑卒中和短暂性脑缺血发作二级预防指南[J]. 中华神经科杂志,2015,48(4):258-273.
    [13] 脑小血管病诊治专家共识组. 中国脑小血管病诊治专家共识[J]. 中华内科杂志,2015,52(10):893-896.
    [14] 中华医学会心血管病学分会,中国老年学学会心脑血管病专业委员会. 华法林抗凝治疗的中国专家共识[J]. 中华外科杂志,2012,52(1):76-82.
    [15] Kearon C,Akl EA,Comerota AJ,et al. Antithrombotic therapy for VTE disease:Antithrombotic therapy and prevention of thrombosis,9th ed:American college of chest physicians evidence-based clinical practice guidelines[J].Chest,2012,141(2 Suppl):e419S-e494S.
  • 加载中
通讯作者: 陈斌, [email protected]
  • 1. 

    沈阳化工大学材料科学与工程学院 沈阳 110142

  1. 本站搜索
  2. 百度学术搜索
  3. 万方数据库搜索
  4. CNKI搜索

Article Metrics

Article views(3071) PDF downloads(379) Cited by()

Related
Proportional views

Clinical pharmacists participating in antithrombotic treatment in subacute myocardial infarction patient with cerebral lacuna infarction and deep vein thrombosis

doi: 10.3969/j.issn.1006-0111.2017.02.016

Abstract: Objective To discuss antithrombotic drug treatment in subacute myocardial infarction patient with cerebral lacuna infarction and deep vein thrombosis. Methods Clinical pharmacists analyzed the causes of the blood clot formation, assessed ischemia and hemorrhage risk, consulted evidence-based medicine information, put forward reasonable suggestions and monitored the medication efficacy and safety. Results There were a lot of risk factors of thrombosis in this patient who was also at high risk of bleeding. Clinical pharmacists recommended to reduce aspirin dose to 75 mg daily and add proton pump inhibitors. Anticoagulant therapy should also include low molecular heparin. Some suggestions were accepted by doctors. The patient's condition was improved and there was no bleeding during hospitalization. Conclusion Clinical pharmacists assisted doctors in the antithrombotic treatment and maximized medication safety.

YANG Xian, ZHENG Ping. Clinical pharmacists participating in antithrombotic treatment in subacute myocardial infarction patient with cerebral lacuna infarction and deep vein thrombosis[J]. Journal of Pharmaceutical Practice and Service, 2017, 35(2): 161-164. doi: 10.3969/j.issn.1006-0111.2017.02.016
Citation: YANG Xian, ZHENG Ping. Clinical pharmacists participating in antithrombotic treatment in subacute myocardial infarction patient with cerebral lacuna infarction and deep vein thrombosis[J]. Journal of Pharmaceutical Practice and Service, 2017, 35(2): 161-164. doi: 10.3969/j.issn.1006-0111.2017.02.016
Reference (15)

Catalog

    /

    DownLoad:  Full-Size Img  PowerPoint
    Return
    Return